Urine Drug Testing Among Patients Prescribed Long-Term Opioid Therapy: Patient and Clinician Factors

References

1. 1.↵
   1. Dowell D,
   2. Haegerich TM,
   3. Chou R

   . CDC guideline for prescribing opioids for chronic pain—United States, 2016. Jama 2016;315:1624–45.

   OpenUrlCrossRefPubMed
2. 2.↵
   1. Manchikanti L,
   2. Kaye A,
   3. Knezevic NN,
   4. et al

   . Responsible, safe, and effective prescription of opioids for chronic non-cancer pain: American Society of Interventional Pain Physicians (ASIPP) Guidelines. Pain Physician 2017;20:S3–S92.

   OpenUrlPubMed
3. 3.↵
   1. Argoff CE,
   2. Alford DP,
   3. Fudin J,
   4. et al

   . Rational urine drug monitoring in patients receiving opioids for chronic pain: consensus recommendations. Pain Med 2018;19:97–117.

   OpenUrl
4. 4.↵
   1. Turner JA,
   2. Saunders K,
   3. Shortreed SM,
   4. et al

   . Chronic opioid therapy risk reduction initiative: impact on urine drug testing rates and results. J Gen Intern Med 2014;29:305–11.

   OpenUrlCrossRefPubMed
5. 5.↵
   1. Larochelle MR,
   2. Cruz R,
   3. Kosakowski S,
   4. et al

   . Do urine drug tests reveal substance misuse among patients prescribed opioids for chronic pain? J Gen Intern Med 2022;37:2365–72. Epub 2021 Aug 17.

   OpenUrl
6. 6.↵
   1. Sherman KJ,
   2. Walker RL,
   3. Saunders K,
   4. et al

   . Doctor-patient trust among chronic pain patients on chronic opioid therapy after opioid risk reduction initiatives: a survey. J Am Board Fam Med 2018;31:578–87.

   OpenUrlAbstract/FREE Full Text
7. 7.↵
   1. Katz NP,
   2. Sherburne S,
   3. Beach M,
   4. et al

   . Behavioral monitoring and urine toxicology testing in patients receiving long-term opioid therapy. Anesth Analg 2003;97:1097–102.

   OpenUrlPubMedWeb of Science
8. 8.↵
   1. Becker WC,
   2. Starrels JL,
   3. Heo M,
   4. et al

   . Racial differences in primary care opioid risk reduction strategies. Ann Fam Med 2011;9:219–25.

   OpenUrlAbstract/FREE Full Text
9. 9.↵
   1. Gaither JR,
   2. Gordon K,
   3. Crystal S,
   4. et al

   . Racial disparities in discontinuation of long-term opioid therapy following illicit drug use among black and white patients. Drug Alcohol Depend 2018;192:371–6.

   OpenUrlPubMed
10. 10.↵
    1. Chua I,
    2. Petrides AK,
    3. Schiff GD,
    4. et al

    . Provider misinterpretation, documentation, and follow-up of definitive urine drug testing results. J Gen Intern Med 2020;35:283–90.

    OpenUrl
11. 11.↵
    1. Eddy DM

    . Variations in physician practice: the role of uncertainty. Health Aff (Millwood) 1984;3:74–89.

    OpenUrlCrossRefPubMed
12. 12.↵
    1. Dowell D,
    2. Ragan KR,
    3. Jones CM,
    4. et al

    . CDC clinical practice guideline for prescribing opioids for pain—United States, 2022. MMWR Recomm Rep 2022;71:1–95.

    OpenUrl
13. 13.↵
    VA/DoD Clinical Practice Guideline. (2022). Use of Opioids in the Management of Chronic Pain Work Group. Washington, DC: U.S. Government Printing Office.
14. 14.↵
    NIDA. Improving opioid prescribing. National Institute on Drug Abuse. Available from: https://nida.nih.gov/publications/improving-opioid-prescribing. March 30, 2017 Accessed December 19, 2022.